<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340089</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1059</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091059</ELocationID><Abstract><AbstractText><b>Background:</b> Conventional vaccines rarely cause severe allergic reactions. However, the rapid development and approval of COVID-19 vaccines left limited initial data on their adverse reactions, particularly in individuals with a history of allergy. The aim of this study was to assess and compare the safety profile of different doses and brands of COVID-19 vaccines in subjects with a history of allergy vs. those without a history of allergy. <b>Methods:</b> From February 2021 to February 2023, a web-based prospective study gathered vaccinee-reported outcomes using electronic questionnaires across eleven European countries. Baseline and up to six follow-up questionnaires captured data on vaccinee demographics, as well as both solicited and unsolicited adverse reactions. <b>Results:</b> Overall, 3476 vaccinees with a history of allergy were matched with 13,872 vaccinees from the general population at the first vaccination cycle and were included in the analysis. A total of 825 vaccinees with a history of allergy who had received a booster dose, matched to 3297 vaccinees from the general population, were included in the analysis. Higher rates of ADRs occurred after the first vaccination cycle compared to after the booster dose (64-91% vs. 56-79%). However, most reported ADRs were solicited and not serious, and no case of anaphylaxis was reported. Women and vaccinees with a history of allergy reported ADRs more frequently than men and the matched controls, respectively. Compared to other COVID-19 vaccines, a higher proportion of vaccinees experiencing at least one ADR following their first vaccination cycle was observed with Comirnaty and Vaxzevria. Statistically significant differences were observed among the study cohorts for median TTO after the second dose, and for median TTR following the first vaccination cycle and booster dose (<i>p</i> &lt; 0.001). <b>Conclusions:</b> Typically, any drug or vaccine use carries a risk of severe allergic reactions, yet the benefits of vaccination generally outweigh these potential risks, as shown with the COVID-19 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luxi</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccimarra</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellitto</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0000-5552-1506</Identifier><AffiliationInfo><Affiliation>Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raethke</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hunsel</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of PharmacoTherapy, Epidemiology &amp; Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9712 Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieber</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulder</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L'Abbate</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Francisco Batel</ForeName><Initials>FB</Initials><Identifier Source="ORCID">0000-0003-4031-7339</Identifier><AffiliationInfo><Affiliation>Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furci</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5062-3076</Identifier><AffiliationInfo><Affiliation>Provincial Healthcare Unit, Section of Allergy, 89900 Vibo Valentia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farcas</LastName><ForeName>Andreea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmacovigilance Research Center, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giele-Eshuis</LastName><ForeName>Janneke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Data Science and Biostatistics, Julius Global Health, University Medical Centre Utrecht, 3584 Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morton</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Drug Safety Research Unit, Southampton SO31 1AA, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Portsmouth, Portsmouth PO1 2UP, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonderlichová</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2691-0582</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, SLOVACRIN, Pavol Jozef Šafárik University in Košice, 040 01 Košice, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurin</LastName><ForeName>Nicolas H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0003-3589-0819</Identifier><AffiliationInfo><Affiliation>University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villalobos</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6907-8354</Identifier><AffiliationInfo><Affiliation>Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riefolo</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6762-2619</Identifier><AffiliationInfo><Affiliation>Teamit Institute, Partnerships, Barcelona Health Hub, 08025 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Miriam C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Data Science and Biostatistics, Julius Global Health, University Medical Centre Utrecht, 3584 Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trifirò</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1147-7296</Identifier><AffiliationInfo><Affiliation>Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S01-FWC EMA/2018/23/PE</GrantID><Agency>European Medicines Agency</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">adverse reactions</Keyword><Keyword MajorTopicYN="N">allergy history</Keyword><Keyword MajorTopicYN="N">anaphylaxis</Keyword><Keyword MajorTopicYN="N">safety profile</Keyword></KeywordList><CoiStatement>Miriam Sturkenboom is the head of a department that conducts studies for regulatory agencies and pharmaceutical companies, which provide research grants to the institution; they include Pfizer, Janssen, and AstraZeneca. All studies were conducted according to the ENCePP code of conduct. Gianluca Trifrò has served in the last three years on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead, and Amgen, He was the scientific director of a master’s program on pharmacovigilance, pharmacoepidemiology, and real-world evidence which has received a non-conditional grant from various pharmaceutical companies. He coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding to conduct observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, and PTC Pharmaceuticals). He is also the scientific coordinator of the academic spin-off “INSPIRE srl” which has received funding to conduct observational studies from contract research organizations (RTI Health Solutions and Pharmo Institute N.V.). None of these listed activities are related to the topic of the manuscript. Francesco Ciccimarra, Nicoletta Luxi, Chiara Bellitto, Luca L’Abbate, Monika Raethke, Florence van Hunsel, Thomas Lieber, Erik Mulder, Fabio Riefolo, Caroline Dureau-Pournin, Andreea Farcas, Francisco Batel Marques, Kathryn Morton, Debabrata Roy, Simona Sonderlichová, Nicolas H. Thurin, and Felipe Villalobos have no conflicts of interest that are directly relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340089</ArticleId><ArticleId IdType="pmc">PMC11435548</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091059</ArticleId><ArticleId IdType="pii">vaccines12091059</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Luxi N., Giovanazzi A., Arcolaci A., Bonadonna P., Crivellaro M.A., Cutroneo P.M., Ferrajolo C., Furci F., Guidolin L., Moretti U., et al. Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs. 2022;36:443–458. doi: 10.1007/s40259-022-00536-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-022-00536-8</ArticleId><ArticleId IdType="pmc">PMC9190452</ArticleId><ArticleId IdType="pubmed">35696066</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgsteede S.D., Geersing T.H., Tempels-Pavlica Ž. Other Excipients than PEG Might Cause Serious Hypersensitivity Reactions in COVID-19 Vaccines. Allergy. 2021;76:1941–1942. doi: 10.1111/all.14774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14774</ArticleId><ArticleId IdType="pmc">PMC8441744</ArticleId><ArticleId IdType="pubmed">34128559</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre for Disease Control and Prevention (CDC) Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination.  [(accessed on 23 July 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html.</Citation></Reference><Reference><Citation>Sampath V., Rabinowitz G., Shah M., Jain S., Diamant Z., Jesenak M., Rabin R., Vieths S., Agache I., Akdis M., et al. Vaccines and Allergic Reactions: The Past, the Current COVID-19 Pandemic, and Future Perspectives. Allergy. 2021;76:1640–1660. doi: 10.1111/all.14840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14840</ArticleId><ArticleId IdType="pmc">PMC8251022</ArticleId><ArticleId IdType="pubmed">33811364</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson L., Brockow K., Alm J., Cardona V., Caubet J.-C., Gomes E., Jenmalm M.C., Lau S., Netterlid E., Schwarze J., et al. Vaccination and Allergy: EAACI Position Paper, Practical Aspects. Pediatr. Allergy Immunol. 2017;28:628–640. doi: 10.1111/pai.12762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.12762</ArticleId><ArticleId IdType="pubmed">28779496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska M., Eiwegger T., Ollert M., Torres M.J., Barber D., Del Giacco S., Jutel M., Nadeau K.C., Palomares O., Rabin R.L., et al. EAACI Statement on the Diagnosis, Management and Prevention of Severe Allergic Reactions to COVID-19 Vaccines. Allergy. 2021;76:1629–1639. doi: 10.1111/all.14739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14739</ArticleId><ArticleId IdType="pmc">PMC8013422</ArticleId><ArticleId IdType="pubmed">33452689</ArticleId></ArticleIdList></Reference><Reference><Citation>clinicaltrials.gov COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations (SARS)  [(accessed on 23 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04761822.</Citation></Reference><Reference><Citation>Shimabukuro T., Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021;325:780. doi: 10.1001/jama.2021.0600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0600</ArticleId><ArticleId IdType="pmc">PMC8892260</ArticleId><ArticleId IdType="pubmed">33475702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian S., Li L., Wang Z., Cui L., Xu Y., Guan K., Zhao B. Allergic Reactions After the Administration of COVID-19 Vaccines. Front. Public Health. 2022;10:878081. doi: 10.3389/fpubh.2022.878081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.878081</ArticleId><ArticleId IdType="pmc">PMC9152252</ArticleId><ArticleId IdType="pubmed">35655467</ArticleId></ArticleIdList></Reference><Reference><Citation>Filon F.L., Lazzarato I., Patriarca E., Iavernig T., Peratoner A., Perri G., Ponis G., Rocco G., Cegolon L. Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) Vaccines. 2022;10:1616. doi: 10.3390/vaccines10101616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101616</ArticleId><ArticleId IdType="pmc">PMC9607499</ArticleId><ArticleId IdType="pubmed">36298481</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavit R., Maoz-Segal R., Iancovici-Kidon M., Offengenden I., Haj Yahia S., Machnes Maayan D., Lifshitz-Tunitsky Y., Niznik S., Frizinsky S., Deutch M., et al. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Netw. Open. 2021;4:e2122255. doi: 10.1001/jamanetworkopen.2021.22255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.22255</ArticleId><ArticleId IdType="pmc">PMC8408666</ArticleId><ArticleId IdType="pubmed">34463744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C., Qiu F., Lou C., Fang L., Liu F., Zhong J., Sun W., Ding W., Yu X., Xu Q., et al. Safety of Inactivated SARS-CoV-2 Vaccines in Patients with Allergic Diseases. Respir. Res. 2022;23:133. doi: 10.1186/s12931-022-02054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02054-1</ArticleId><ArticleId IdType="pmc">PMC9137440</ArticleId><ArticleId IdType="pubmed">35624516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara A., Coskun A., Temel F., Özelci P., Topal S., Ates İ. Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVACTM) among General and High-Risk Population. Vaccines. 2023;11:437. doi: 10.3390/vaccines11020437.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020437</ArticleId><ArticleId IdType="pmc">PMC9958953</ArticleId><ArticleId IdType="pubmed">36851314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadizar F., Luxi N., Raethke M., Schmikli S., Riefolo F., Saraswati P.W., Bucsa C., Osman A., Liddiard M., Maques F.B., et al. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials. Drug Saf. 2023;46:575–585. doi: 10.1007/s40264-023-01304-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-023-01304-5</ArticleId><ArticleId IdType="pmc">PMC10136385</ArticleId><ArticleId IdType="pubmed">37103643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccimarra F., Luxi N., Bellitto C., L’Abbate L., Raethke M., van Hunsel F., Lieber T., Mulder E., Riefolo F., Dureau-Pournin C., et al. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study. Vaccines. 2024;12:241. doi: 10.3390/vaccines12030241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030241</ArticleId><ArticleId IdType="pmc">PMC10974422</ArticleId><ArticleId IdType="pubmed">38543875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellitto C., Luxi N., Ciccimarra F., L’Abbate L., Raethke M., van Hunsel F., Lieber T., Mulder E., Riefolo F., Villalobos F., et al. What Is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European “COVID Vaccine Monitor” Active Surveillance Study. Drug Saf. 2024;47:1011–1023. doi: 10.1007/s40264-024-01449-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-024-01449-x</ArticleId><ArticleId IdType="pmc">PMC11399172</ArticleId><ArticleId IdType="pubmed">38907947</ArticleId></ArticleIdList></Reference><Reference><Citation>Meddra.org Introductory Guide for Standardised MedDRA Queries (SMQs) Version 24.0.  [(accessed on 23 July 2024)].  Available online:  https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_24_0_English.pdf.</Citation></Reference><Reference><Citation>COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (CIOMS)  Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII.  [(accessed on 23 July 2024)].  Available online:  https://cioms.ch/publications/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/</Citation></Reference><Reference><Citation>Luxi N., Riefolo F., Raethke M., van Hunsel F., Sturkenboom M., Trifirò G. COVID-19 Vaccine Monitor: Final Study Report for Cohort Event Monitoring of Vaccinated Persons. Zenodo. preprints .</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8298359</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic A., Riad A., Attia S., Klugar M., Tanasiewicz M. Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. J. Clin. Med. 2021;10:5338. doi: 10.3390/jcm10225338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225338</ArticleId><ArticleId IdType="pmc">PMC8623766</ArticleId><ArticleId IdType="pubmed">34830620</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 MRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 NCoV-19) COVID-19 Vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Macy E., Pandya S., Sheikh J., Burnette A., Shi J.M., Chung J., Gin N., Crawford W., Zhang J. Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 MRNA Vaccination–Associated Hypersensitivity Reactions. J. Allergy Clin. Immunol. Pract. 2022;10:827–836. doi: 10.1016/j.jaip.2021.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2021.12.021</ArticleId><ArticleId IdType="pmc">PMC8714255</ArticleId><ArticleId IdType="pubmed">34971845</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Robinson L.B., Patel R., Landman A.B., Fu X., Shenoy E.S., Hashimoto D.M., Banerji A., Wickner P.G., Samarakoon U., et al. Association of Self-Reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination. JAMA Netw. Open. 2021;4:e2131034. doi: 10.1001/jamanetworkopen.2021.31034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.31034</ArticleId><ArticleId IdType="pmc">PMC8548941</ArticleId><ArticleId IdType="pubmed">34698847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brabete A.C., Greaves L., Maximos M., Huber E., Li A., Lê M.-L. A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases. Pharmaceuticals. 2022;15:298. doi: 10.3390/ph15030298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15030298</ArticleId><ArticleId IdType="pmc">PMC8950058</ArticleId><ArticleId IdType="pubmed">35337096</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum H.G., Gee J., Liu R., Marquez P.L., Zhang B., Strid P., Abara W.E., McNeil M.M., Myers T.R., Hause A.M., et al. Safety of MRNA Vaccines Administered during the Initial 6 Months of the US COVID-19 Vaccination Programme: An Observational Study of Reports to the Vaccine Adverse Event Reporting System and v-Safe. Lancet Infect. Dis. 2022;22:802–812. doi: 10.1016/S1473-3099(22)00054-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00054-8</ArticleId><ArticleId IdType="pmc">PMC8901181</ArticleId><ArticleId IdType="pubmed">35271805</ArticleId></ArticleIdList></Reference><Reference><Citation>Raethke M., van Hunsel F., Luxi N., Lieber T., Bellitto C., Mulder E., Ciccimarra F., Riefolo F., Thurin N.H., Roy D., et al. Frequency and Timing of Adverse Reactions to COVID-19 Vaccines; A Multi-Country Cohort Event Monitoring Study. Vaccine. 2024;42:2357–2369. doi: 10.1016/j.vaccine.2024.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.03.001</ArticleId><ArticleId IdType="pubmed">38448322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M.S., Amarasinghe A., Greenhawt M., Kelso J.M., Kochhar S., Yu-Hor Thong B., Top K.A., Turner P.J., Worm M., Law B. Anaphylaxis: Revision of the Brighton Collaboration Case Definition. Vaccine. 2023;41:2605–2614. doi: 10.1016/j.vaccine.2022.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.11.027</ArticleId><ArticleId IdType="pubmed">36435707</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreskin S.C., Halsey N.A., Kelso J.M., Wood R.A., Hummell D.S., Edwards K.M., Caubet J.-C., Engler R.J.M., Gold M.S., Ponvert C., et al. International Consensus (ICON): Allergic Reactions to Vaccines. World Allergy Organ. J. 2016;9:32. doi: 10.1186/s40413-016-0120-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40413-016-0120-5</ArticleId><ArticleId IdType="pmc">PMC5026780</ArticleId><ArticleId IdType="pubmed">27679682</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal K.G., Greenhawt M., Phillips E.J., Agmon-Levin N., Golden D.B.K., Shaker M. An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding. J. Allergy Clin. Immunol. Pract. 2023;11:3305–3318. doi: 10.1016/j.jaip.2023.06.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2023.06.057</ArticleId><ArticleId IdType="pubmed">37414339</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria A., Labella M., Doña I., Nicaise-Roland P., Chollet-Martin S., Autegarden J., Castagna J., Le Thai C., de Chaisemartin L., Torres M.J., et al. Risk Stratification through Extensive Allergy Work-up in COVID-19-mRNA Vaccine Allergic Reactions. Allergy. 2023;78:2320–2323. doi: 10.1111/all.15715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15715</ArticleId><ArticleId IdType="pubmed">36971457</ArticleId></ArticleIdList></Reference><Reference><Citation>Padilla-Flores T., Sampieri A., Vaca L. Incidence and management of the main serious adverse events reported after COVID-19 vaccination. Pharmacol Res Perspect. 2024;12:e1224. doi: 10.1002/prp2.1224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.1224</ArticleId><ArticleId IdType="pmc">PMC11167235</ArticleId><ArticleId IdType="pubmed">38864106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanillas B., Novak N. Allergy to COVID-19 Vaccines: A Current Update. Allergol. Int. 2021;70:313–318. doi: 10.1016/j.alit.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.alit.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8062405</ArticleId><ArticleId IdType="pubmed">33962863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaggers J., Samarakoon U., Fu X., Gonzalez-Estrada A., Anvari S., Chong H.J., Van Meerbeke S.W., Petrov A.A., Chow T.G., Banerji A., et al. Anaphylaxis after COVID-19 Vaccination: A Registry-Based Study. J. Allergy Clin. Immunol. Pract. 2022;10:3020–3023. doi: 10.1016/j.jaip.2022.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.08.008</ArticleId><ArticleId IdType="pmc">PMC9371767</ArticleId><ArticleId IdType="pubmed">35964925</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal K.G., Robinson L.B., Camargo C.A., Shenoy E.S., Banerji A., Landman A.B., Wickner P. Acute Allergic Reactions to MRNA COVID-19 Vaccines. JAMA. 2021;325:1562. doi: 10.1001/jama.2021.3976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3976</ArticleId><ArticleId IdType="pmc">PMC7941251</ArticleId><ArticleId IdType="pubmed">33683290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu D.K., Abrams E.M., Golden D.B.K., Blumenthal K.G., Wolfson A.R., Stone C.A., Krantz M.S., Shaker M., Greenhawt M. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines. JAMA Intern. Med. 2022;182:376. doi: 10.1001/jamainternmed.2021.8515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.8515</ArticleId><ArticleId IdType="pmc">PMC8861900</ArticleId><ArticleId IdType="pubmed">35188528</ArticleId></ArticleIdList></Reference><Reference><Citation>van Maaren M., Rijnenberg D., Roovers T.H.W.M., van de Ven A., Pleijhuis R.G., Rustemeyer T., van Daele P., Rockmann H., Rombach S.M. Letter Identification of Persons Who May Respond Severely to a Hospital-Administered COVID-19 Vaccine: Lessons Learned in the Netherlands during the COVID-19 Pandemic. Authorea. 2023.  [(accessed on 23 July 2024)].  Available online:  https://www.authorea.com/users/672515/articles/671560-letter-identification-of-persons-who-may-respond-severely-to-a-hospital-administered-covid-19-vaccine-lessons-learned-in-the-netherlands-during-the-covid-19-pandemic.</Citation></Reference><Reference><Citation>Robinson L.B., Fu X., Hashimoto D., Wickner P., Shenoy E.S., Landman A.B., Blumenthal K.G. Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatol. 2021;157:1000. doi: 10.1001/jamadermatol.2021.2114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2021.2114</ArticleId><ArticleId IdType="pmc">PMC8223130</ArticleId><ArticleId IdType="pubmed">34160555</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlowski P.M., Jedlowski M.F. Morbilliform Rash after Administration of Pfizer-BioNTech COVID-19 MRNA Vaccine. Dermatol. Online J. 2021;27:20. doi: 10.5070/D3271052044.</Citation><ArticleIdList><ArticleId IdType="doi">10.5070/D3271052044</ArticleId><ArticleId IdType="pubmed">33560802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson A.R., Freeman E.E., Blumenthal K.G. Urticaria 12 Days After COVID-19 MRNA Booster Vaccination. JAMA. 2022;327:1702. doi: 10.1001/jama.2022.5247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.5247</ArticleId><ArticleId IdType="pubmed">35420647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pescosolido E., Muller Y.D., Sabaté-Brescó M., Ferrer M., Yerly D., Caubet J., Lantin J., Ribi C., Bergmann M.M. Clinical and Immunological Data from Chronic Urticaria Onset after MRNA SARS-CoV-2 Vaccines. Clin. Exp. Allergy. 2022;52:1343–1346. doi: 10.1111/cea.14214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.14214</ArticleId><ArticleId IdType="pmc">PMC9539124</ArticleId><ArticleId IdType="pubmed">35962744</ArticleId></ArticleIdList></Reference><Reference><Citation>Purayil S., Thalappil S., Al-Nesf M., Kocaturk E. Chronic Urticaria and COVID-19 Vaccination: Qatar Data (Preliminary Report of COVAC-CU-International) Qatar Med. J. 2022;2022:1–2. doi: 10.5339/qmj.2022.fqac.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.5339/qmj.2022.fqac.2</ArticleId><ArticleId IdType="pmc">PMC9340567</ArticleId><ArticleId IdType="pubmed">35968517</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd A., Samarakoon U., Wolfson A.R., Banerji A., Freeman E.E., Blumenthal K.G. Urticaria after COVID-19 Vaccination and Vaccine Hesitancy. J. Allergy Clin. Immunol. Pract. 2023;11:958–960. doi: 10.1016/j.jaip.2022.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.12.010</ArticleId><ArticleId IdType="pmc">PMC9791784</ArticleId><ArticleId IdType="pubmed">36581074</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal K.G., Freeman E.E., Saff R.R., Robinson L.B., Wolfson A.R., Foreman R.K., Hashimoto D., Banerji A., Li L., Anvari S., et al. Delayed Large Local Reactions to MRNA-1273 Vaccine against SARS-CoV-2. N. Engl. J. Med. 2021;384:1273–1277. doi: 10.1056/NEJMc2102131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102131</ArticleId><ArticleId IdType="pmc">PMC7944952</ArticleId><ArticleId IdType="pubmed">33657292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>